Integrated approach to the treatment of palmoplantar psoriasis (case report)
DOI: 10.32364/2587-6821-2025-9-6-9
A.A. Arsenyeva, E.V. Treneva, E.V. Orlov, S.V. Bulgakova, Y.M. Pakhomova, D.P. Kurmaev
Samara State Medical University, Samara, Russian Federation
Psoriasis is a chronic, multifactorial inflammatory disease that can present in various clinical forms. In addition to affecting smooth skin, this condition may involve skin folds, joints (psoriatic arthritis), and nails. Due to the diversity of clinical presentations and the varying degrees of disease severity, universal therapeutic protocols for psoriasis have not yet been established. An especially challenging subgroup includes patients with psoriasis occurring alongside comorbidities, which imposes additional requirements on therapy selection.
This article presents a case report of a patient with palmoplantar pustulosis in the setting of multiple comorbidities, including type 2 diabetes mellitus, hepatitis C, and HIV infection. Following a course of systemic therapy and a topical combination medication, resolution of psoriatic plaques and the absence of new lesions or scaling were observed after four weeks. Optimizing the management of palmoplantar pustulosis, particularly in patients with concomitant diseases, requires a multidisciplinary approach that includes collaboration among dermatologists, endocrinologists, hepatologists, and infectious disease specialists.
Keywords: psoriasis, palmoplantar pustulosis, hepatitis C, diabetes mellitus, HIV infection, cytostatics, hepatoprotectors, biologic therapy, topical corticosteroids.
For citation: Arsenyeva A.A., Treneva E.V., Orlov E.V., Bulgakova S.V., Pakhomova Y.M., Kurmaev D.P. Integrated approach to the treatment of palmoplantar psoriasis (case report). Russian Medical Inquiry. 2025;9(6):353–356 (in Russ.). DOI: 10.32364/2587-6821-2025-9-6-9
About the authors:
Antonina A. Arsenyeva — C. Sc. (Med.), Head of the Department of Dermatovenerology and Cosmetology at the Institute of Professional Education; Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0002-7933-3515
Ekaterina V. Treneva — C. Sc. (Med.), Associate Professor of the Department of Endocrinology and Geriatrics, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0003-0097-7252
Evgeny V. Orlov — Dr. Sc. (Med.), Professor of the Department of Dermatovenerology and Cosmetology at the Institute of Professional Education; Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0002-2220-793X
Svetlana V. Bulgakova — Dr. Sc. (Med.), Associate Professor of the Department of Endocrinology and Geriatrics, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0003-0027-1786
Yulia M. Pakhomova — Assistant Professor of the Department of Dermatovenerology and Cosmetology at the Institute of Professional Education, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0009-0009-0844-5745
Dmitry P. Kurmaev — C. Sc. (Med.), Assistant Professor of the Department of Endocrinology and Geriatrics, Samara State Medical University; 89, Chapaevskaya str., Samara, 443099, Russian Federation; ORCID iD 0000-0003-4114-5233
Contact information: Antonina A. Arsenyeva, e-mail: a.a.arseneva@samsmu.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 25.04.2025.
Revised 26.05.2025.
Accepted 20.06.2025.
2. Круглова Л.С., Бакулев А.Л., Коротаева Т.В. и др. Псориаз. М.: ГЭОТАР-Медиа; 2022.Kruglova L.S., Bakulev A.L., Korotaeva T.V. et al. Psoriasis. M.: GEOTAR-Media; 2022 (in Russ.).
3. Круглова Л.С., Коротаева Т.В. Программа медико-социального сопровождения пациентов с псориазом и (или) псориатическим артритом, которым показана терапия генно-инженерными биологическими препаратами в условиях реальной клинической практики. Научно-практическая ревматология. 2020;58(5):495–502. DOI: 10.47360/1995-4484-2020-495-502Kruglova L.S., Korotaeva T.V. Medical and social care program for patients with psoriasis and/or psoriatic arthritis eligible for biological dmards in real clinical practice. Rheumatology Science and Practice. 2020;58(5):495–502 (in Russ.). DOI: 10.47360/1995-4484-2020-495-502
4. Удалова И.В., Герасимова Д.Д., Гульянц Н.М., Охлопков В.А. Многоликий псориаз: ведение пациентов в условиях современного многопрофильного медицинского центра. Вестник МЕДСИ. 2024;2(35). (Электронный ресурс.) URL: https://vestnik.medsi.ru/publications/543 (дата обращения: 20.06.2025).Udalova I.V., Gerasimova D.D., Gulyants N.M., Okhlopkov V.A. Multifaceted psoriasis: patient management in a modern multidisciplinary medical center. MEDSI Bulletin. 2024;2(35). (Electronic resource.) URL: https://vestnik.medsi.ru/publications/543 (in Russ.) (access date: 20.06.2025).
5. Shapiro J., Cohen A.D., David M. et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case–control study. J Am Acad Dermatol. 2007;56(4):629–634. DOI: 10.1016/j.jaad.2006.09.017
6. Бакулев А.Л., Шагова Ю.В., Козлова И.В. Псориаз как системная патология. Саратовский научно-медицинский журнал. 2008;1:13–19.Bakulev A.L., Shagova Yu.V., Kozlova I.V. Psoriasis as a systemic pathology. Saratov Journal of Medical Scientific Research. 2008;1:13–19 (in Russ.).
7. Бакулев А.Л., Кравченя С.С. Применение гепатопротекторов при псориазе: сравнительная клинико-лабораторная и ультрасонографическая оценка эффективности. Вестник дерматологии и венерологии. 2010;1:112–117. DOI: 10.25208/vdv880Bakulev A.L., Kravchenya S.S. Administering hepatoprotectors for psoriasis: a comparative clinical, laboratory and ultrasonic assessment of its efficacy. Vestnik dermatologii i venerologii. 2010;1:112–117 (in Russ.). DOI: 10.25208/vdv880
8. Rodríguez-Zúñiga M.J.M., García-Perdomo H.A. Systematic Review and Meta-Analysis of the Association Between Psoriasis and Metabolic Syndrome. J Am Acad Dermatol. 2017;77(4):657–666. DOI: 10.1016/j.jaad.2017.04.1133
9. Лыкова С.Г., Моржанаева М.А., Немчанинова О.Б., Свечникова Е.В. Псориаз у пациентов с метаболическим синдромом: клинические аспекты проблемы. Клиническая дерматология и венерология. 2020;19(2):214–222. DOI: 10.17116/klinderma202019021214Lykova S.G., Morzhanaeva M.A., Nemchaninova O.B., Svechnikova E.V. Psoriasis in patients with metabolic syndrome: clinical aspects of the problem. Russian Journal of Clinical Dermatology and Venereology. 2020;19(2):214–222 (in Russ.). DOI: 10.17116/klinderma202019021214
10. Armstrong A.W., Schupp C., Bebo B. Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011. Dermatology. 2012;225:121–126. DOI: 10.1159/000342180
11. Рекен М., Шаллер М., Заттлер Э., Бургдорф В. Атлас по дерматологии. МЕДпресс-информ. 2012;174.Röcken M., Schaller M., Sattler E., Burgdorf W. Atlas of Dermatology. MEDpress-inform. 2012;174 (in Russ.).
12. Круглова Л.С., Руднева Н.С., Бакулев А.Л., Хотко А.А. Инверсный псориаз и псориаз «трудных» локализаций: эффективность нетакимаба. Медицинский алфавит. 2022;(27):14–20. DOI: 10.33667/2078-5631-2022-27-14-20Kruglova L.S., Rudneva N.S., Bakulev A.L., Hotko A.A. Inverse psoriasis and psoriasis of ‘difficult' localizations: Effectiveness of netakimab. Medical alphabet. 2022;(27):14–20 (in Russ.). DOI: 10.33667/2078‑5631‑2022‑27‑14‑20
13. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. J Dermatol. 2002;147(3):528–537. DOI: 10.1046/j.1365-2133.2002.05006.x
14. Veien N.K., Olholm Larsen P., Thestrup-Pedersen K. et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br J Dermatol. 1999;140(5):882–886.
15. Соколовский Е.В., Монахов К.Н., Холодилова Н.А. и др. Интермиттирующая терапия бетаметазоном атопического дерматита и экземы кистей. Российский журнал кожных и венерических болезней. 2009;3:16–21.Sokolovsky E.V., Monakhov K.N., Kholodilova N.A. et al. Intermittent betamethasone therapy of atopic dermatitis and hand eczema. Russian Journal of Skin and Venereal Diseases. 2009;3:16–21 (in Russ.).
16. Бахлыкова Е.А., Филимонкова Н.Н., Матусевич С.Л. и др. Пустулезный псориаз: качество жизни пациентов и методы терапии. Практическая медицина. 2014;8(84):27–31.Bakhlykova Е.А., Filimonkova N.N., Matusevich S.L. et al. Pustular psoriasis: patients life quality and methods of treatment. Practical Medicine. 2014;8(84):27–31 (in Russ.).
17. Egeberg А., See К., Garrelts А., Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3. DOI: 10.1186/s12895-020-00099-7
18. Nakamura M., Koo J. Safety considerations with combination therapies for psoriasis. Expert Opin Drug Saf. 2020;19(4):489–498. DOI: 10.1080/14740338.2020.1722640
19. Bernardini N., Skroza N., Tolino E. et al. Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study. Clin Ter. 2020;171(4):e310–e315. DOI: 10.7417/CT.2020.2234
20. Hadeler E., Mosca M., Hong J. et al. Nail Psoriasis: A Review of Effective Therapies and Recommendations for Management. Dermatol Ther (Heidelb). 2021;11(3):799–831. DOI: 10.1007/s13555-021-00523-x
21. Rigopoulos D., Rompoti N., Gregoriou S. Management of Nail Psoriasis. Dermatol Clin. 2021;39(2):211–220. DOI: 10.1016/j.det.2020.12.014
22. Платонова А.В., Жуков А.С., Хайрутдинов В.Р., Самцов А.В. Псориатическая ониходистрофия: индексы оценки степени тяжести (часть 2). Вестник дерматологии и венерологии. 2019;95(1):9–14. DOI: 10.25208/0042-4609-2019-95-1-9-14Platonova A.V., Zhukov A.S., Khairutdinov V.R., Samtsov A.V. Psoriatic onychodystrophy: indices for assessing the severity of psoriatic onychodystrophy (part 2). Vestnik Dermatologii i Venerologii. 2019;95(1):9–14 (in Russ.). DOI: 10.25208/0042-4609-2019-95-1-9-14
This work is licensed under a Creative Commons «Attribution» 4.0 License.
